Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial.

CONTEXT Antiarrhythmic drugs are commonly used for prevention of recurrent atrial fibrillation (AF) despite inconsistent efficacy and frequent adverse effects. Catheter ablation has been proposed as an alternative treatment for paroxysmal AF. OBJECTIVE To determine the efficacy of catheter ablation compared with antiarrhythmic drug therapy (ADT) in treating symptomatic paroxysmal AF. DESIGN, SETTING, AND PARTICIPANTS A prospective, multicenter, randomized (2:1), unblinded, Bayesian-designed study conducted at 19 hospitals of 167 patients who did not respond to at least 1 antiarrhythmic drug and who experienced at least 3 AF episodes within 6 months before randomization. Enrollment occurred between October 25, 2004, and October 11, 2007, with the last follow-up on January 19, 2009. INTERVENTION Catheter ablation (n = 106) or ADT (n = 61), with assessment for effectiveness in a comparable 9-month follow-up period. MAIN OUTCOME MEASURES Time to protocol-defined treatment failure. The proportion of patients who experienced major treatment-related adverse events within 30 days of catheter ablation or ADT was also reported. RESULTS At the end of the 9-month effectiveness evaluation period, 66% of patients in the catheter ablation group remained free from protocol-defined treatment failure compared with 16% of patients treated with ADT. The hazard ratio of catheter ablation to ADT was 0.30 (95% confidence interval, 0.19-0.47; P < .001). Major 30-day treatment-related adverse events occurred in 5 of 57 patients (8.8%) treated with ADT and 5 of 103 patients (4.9%) treated with catheter ablation. Mean quality of life scores improved significantly in patients treated by catheter ablation compared with ADT at 3 months; improvement was maintained during the course of the study. CONCLUSION Among patients with paroxysmal AF who had not responded to at least 1 antiarrhythmic drug, the use of catheter ablation compared with ADT resulted in a longer time to treatment failure during the 9-month follow-up period. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00116428.

[1]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[2]  J. Murabito,et al.  Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality The Framingham Heart Study , 2003, Circulation.

[3]  A. Curtis,et al.  Clinical factors associated with abandonment of a rate-control or a rhythm-control strategy for the management of atrial fibrillation in the AFFIRM study. , 2005, American heart journal.

[4]  Ralph Lazzara,et al.  Comparison of Electrode Cooling Between Internal and Open Irrigation in Radiofrequency Ablation Lesion Depth and Incidence of Thrombus and Steam Pop , 2005, Circulation.

[5]  Tachapong Ngarmukos,et al.  Clinical outcomes of catheter substrate ablation for high-risk patients with atrial fibrillation. , 2008, Journal of the American College of Cardiology.

[6]  Mandeep Bhargava,et al.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. , 2005, JAMA.

[7]  F A Mathewson,et al.  The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. , 1995, The American journal of medicine.

[8]  Silvia G Priori,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commit , 2006, Journal of the American College of Cardiology.

[9]  G. Kay,et al.  Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. , 1996, Circulation.

[10]  R. D'Agostino,et al.  Impact of Atrial Fibrillation on the Risk of Death , 1998 .

[11]  O. Alfieri,et al.  Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation , 2003 .

[12]  C. Good,et al.  Amiodarone to prevent recurrence of atrial fibrillation. , 2000, The New England journal of medicine.

[13]  D. Reda,et al.  Clinical ResearchHeart Rhythm DisorderQuality of Life and Exercise Performance in Patients in Sinus Rhythm Versus Persistent Atrial Fibrillation: A Veterans Affairs Cooperative Studies Program Substudy , 2006 .

[14]  D. Berry.  Bayesian Statistics and the Efficiency and Ethics of Clinical Trials , 2004 .

[15]  D. Berry.  Bayesian clinical trials , 2006, Nature Reviews Drug Discovery.

[16]  Affirm Investigators.  Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. , 2003, Journal of the American College of Cardiology.

[17]  F. Sacher,et al.  Catheter Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation: The A4 Study , 2008, Circulation.

[18]  D. Levy,et al.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.

[19]  V. Santinelli,et al.  Atrial fibrillation progression and management: a 5-year prospective follow-up study. , 2008, Heart rhythm.

[20]  S. Connolly,et al.  Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. , 2002, American heart journal.

[21]  M. Josephson,et al.  Amiodarone versus sotalol for atrial fibrillation. , 2005, The New England journal of medicine.

[22]  Hugh Calkins,et al.  Symptomatic and Asymptomatic Atrial Fibrillation in Patients Undergoing Radiofrequency Catheter Ablation , 2006, Journal of cardiovascular electrophysiology.

[23]  Donald A Berry,et al.  Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis , 2005, Clinical trials.

[24]  J. Blumenthal,et al.  Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. , 1994, The American journal of cardiology.

[25]  V. Santinelli,et al.  A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. , 2006, Journal of the American College of Cardiology.

[26]  EmileDaoud,et al.  Catheter Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation , 2008 .

[27]  M. Chung,et al.  2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation , 2017, Heart rhythm.

[28]  Douglas Packer,et al.  Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation , 2005, Circulation.

[29]  Elia Biganzoli,et al.  Updated Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation , 2005, Circulation. Arrhythmia and electrophysiology.

[30]  Antonio De Simone,et al.  Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). , 2006, European heart journal.

[31]  Ottavio Alfieri,et al.  Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. , 2003, Journal of the American College of Cardiology.

[32]  P. Zimetbaum,et al.  Healthcare Resource Utilization and Costs Associated with Recurrent Episodes of Atrial Fibrillation: The FRACTAL Registry , 2007, Journal of cardiovascular electrophysiology.